601607 上海医药
已收盘 11-13 15:00:00
资讯
新帖
简况
股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第七次会议决议公告》
证券之星 · 11-13 02:21
股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第七次会议决议公告》
上海医药（601607）11月11日主力资金净买入2.01万元
证券之星 · 11-12
上海医药（601607）11月11日主力资金净买入2.01万元
上海医药（601607）11月5日主力资金净卖出429.47万元
证券之星 · 11-06
上海医药（601607）11月5日主力资金净卖出429.47万元
股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》
证券之星 · 11-06
股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》
股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》
证券之星 · 11-05
股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》
上海医药(601607.SH)子公司曲前列尼尔二乙醇胺吸入粉雾剂获临床试验批准
智通财经 · 11-04
上海医药(601607.SH)子公司曲前列尼尔二乙醇胺吸入粉雾剂获临床试验批准
上海医药(601607.SH)控股股东拟增持1100万股至2200万股公司H股股份
智通财经 · 11-04
上海医药(601607.SH)控股股东拟增持1100万股至2200万股公司H股股份
上海医药获得发明专利授权：“GITR结合蛋白及其用途”
证券之星 · 11-02
上海医药获得发明专利授权：“GITR结合蛋白及其用途”
上海医药（601607）2026年三季报简析：增收不增利
证券之星 · 10-31
上海医药（601607）2026年三季报简析：增收不增利
股市必读：上海医药新发布《上海医药集团股份有限公司关于与上海复旦张江生物医药股份有限公司续签《销售及分销协议》暨日常关联交易的公告》
证券之星 · 10-30
股市必读：上海医药新发布《上海医药集团股份有限公司关于与上海复旦张江生物医药股份有限公司续签《销售及分销协议》暨日常关联交易的公告》
上海医药：与上药集团签订房屋租赁框架协议
南方财经网 · 10-29
上海医药：与上药集团签订房屋租赁框架协议
上海医药：第三季度归母净利润10.82亿元 同比上升57.2%
财中社 · 10-29
上海医药：第三季度归母净利润10.82亿元 同比上升57.2%
天士力、上海医药等纷纷终止管线研发：同质化竞争下，缺乏差异化跟随管线“及时止损”
蓝鲸财经 · 10-26
天士力、上海医药等纷纷终止管线研发：同质化竞争下，缺乏差异化跟随管线“及时止损”
上海医药：10月23日融资净买入1001.35万元，连续3日累计净买入1394.24万元
同花顺 · 10-26
上海医药：10月23日融资净买入1001.35万元，连续3日累计净买入1394.24万元
股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》
证券之星 · 10-26
股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》
上海医药终止I025-A研发项目
财中社 · 10-23
上海医药终止I025-A研发项目
上海医药（601607）10月20日主力资金净卖出213.26万元
证券之星 · 10-21
上海医药（601607）10月20日主力资金净卖出213.26万元
【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等
证券之星 · 10-12
【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等
股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》
证券之星 · 10-12
股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》
上海医药(601607.SH)：氯维地平乳状注射液获得批准生产
智通财经 · 10-09
上海医药(601607.SH)：氯维地平乳状注射液获得批准生产
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是药品、医疗器械、大健康产品、医药商业。公司再度入选《财富》世界500强和《PharmExec》2026全球制药企业50强榜单，排名为第411位和第39位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.13,"timestamp":1794553200000,"preClose":16.25,"halted":0,"volume":13814673,"delay":0,"changeRate":-0.0074,"floatShares":2789000000,"shares":3708000000,"eps":1.3924,"marketStatus":"已收盘","change":-0.12,"latestTime":"11-13 15:00:00","open":16.23,"high":16.28,"low":16.07,"amount":223000000,"amplitude":0.0129,"askPrice":16.13,"askSize":181,"bidPrice":16.12,"bidSize":472,"shortable":0,"etf":0,"ttmEps":1.3924,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.25,"symbolType":"stock","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":17.88,"lowLimit":14.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.75,"roa":"--","peRate":11.584315,"roe":"5.9%","epsLYR":1.54,"committee":0.813482,"marketValue":59816000000,"turnoverRate":0.005,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-16。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":10.87,"timestamp":1794557297004,"preClose":10.95,"halted":0,"volume":1292300,"delay":0,"premium":"-42.65"},"floatMarketCap":44990000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2683251974","title":"股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683251974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683251974?lang=zh_cn&edition=full","pubTime":"2026-11-13 02:21","pubTimestamp":1794507670,"startTime":"0","endTime":"0","summary":"公司公告汇总上海医药集团股份有限公司第九届董事会第七次会议决议公告上海医药于2026年11月12日以通讯方式召开第九届董事会第七次会议，应到董事10名，实到10名，会议审议通过《关于上海医药集团股份有限公司估值提升计划暨2026年度“提质增效重回报”2.0行动方案的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300002385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0187","BK0020","BK0184","BK0188","BK0099","BK0012","BK0209","BK1197","601607","BK0097","BK0196","02607","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682366165","title":"上海医药（601607）11月11日主力资金净买入2.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682366165","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682366165?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:31","pubTimestamp":1794443515,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月11日收盘，上海医药报收于16.21元，下跌1.4%，换手率0.51%，成交量14.24万手，成交额2.32亿元。近5日资金流向一览见下表：上海医药融资融券信息显示，融资方面，当日融资买入1785.98万元，融资偿还1298.84万元，融资净买入487.14万元，连续3日净买入累计851.2万元。上海医药主营业务：化学原料药、化学药制剂、抗生素、生化药品、生物制品中成药、医疗器械、制药设备、化学危险物品等的生产、销售及进出口业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200006594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0028","BK0183","BK0184","BK0209","BK0012","02607","BK0020","BK1197","BK0187","BK0097","BK0188","601607","BK0099","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681849968","title":"上海医药（601607）11月5日主力资金净卖出429.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681849968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681849968?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:34","pubTimestamp":1793925283,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，上海医药报收于16.81元，下跌0.3%，换手率0.51%，成交量14.21万手，成交额2.39亿元。近5日资金流向一览见下表：上海医药融资融券信息显示，融资方面，当日融资买入3020.18万元，融资偿还2454.27万元，融资净买入565.9万元。上海医药主营业务：化学原料药、化学药制剂、抗生素、生化药品、生物制品中成药、医疗器械、制药设备、化学危险物品等的生产、销售及进出口业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0099","BK0187","BK0209","BK0196","02607","BK0028","BK0097","BK0175","BK0184","BK0020","BK1197","BK0183","BK0012","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681005146","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681005146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681005146?lang=zh_cn&edition=full","pubTime":"2026-11-06 02:06","pubTimestamp":1793901979,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药出资3亿元参与设立的上海上实生物医药产业私募基金已完成私募投资基金备案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600002193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","02607","BK0099","BK1197","BK0196","BK0209","BK0028","BK0188","161726","BK0184","BK0183","BK0012","BK0097","601607","BK0175","BK0187","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681069645","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681069645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681069645?lang=zh_cn&edition=full","pubTime":"2026-11-05 01:52","pubTimestamp":1793814759,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药出资3亿元参与设立的上海上实生物医药产业私募基金已完成私募投资基金备案。公司公告汇总：子公司上药睿尔收到曲前列尼尔二乙醇胺吸入粉雾剂临床试验批准通知书，该药为2.2类改良型创新药，拟用于治疗肺动脉高压。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500003526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK1197","BK0028","399441","BK0012","BK0097","BK0183","BK0184","601607","BK0020","BK0187","BK0188","BK0209","02607","161726","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680033020","title":"上海医药(601607.SH)子公司曲前列尼尔二乙醇胺吸入粉雾剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680033020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680033020?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:53","pubTimestamp":1793782399,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药睿尔药品有限公司收到国家药品监督管理局核准签发的关于曲前列尼尔二乙醇胺吸入粉雾剂的《药物临床试验批准通知书》。据悉，曲前列尼尔二乙醇胺吸入粉雾剂为2.2类改良型创新药，活性成分是曲前列尼尔二乙醇胺，为人工合成前列环素类衍生物，拟用于治疗肺动脉高压(PAH，WHO第1组)，以减轻运动引起的相关症状，其作用机制主要通过直接舒张肺和全身动脉血管床并抑制血小板聚集来发挥作用。截至公告披露日，该项目已累计投入研发费用约2141万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","02607","BK0028","BK1197","BK0187","601607","BK0175","IBBQ","MDTX","BK0020","BK0184","BK0099","BK0097","BK0012","BK0188","BK0196","BK0183","BK0209","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680795033","title":"上海医药(601607.SH)控股股东拟增持1100万股至2200万股公司H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680795033","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680795033?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:47","pubTimestamp":1793782078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，公司控股股东上海实业(集团)有限公司计划在未来12个月内由其全资子公司上实国际投资有限公司(简称“上实国际”)，通过香港联合交易所有限公司系统以集中竞价方式增持公司H股股份，增持股份总量1100万股至2200万股，不超过公司有投票权股份数的1%。上实国际于2026年11月2日增持公司80万股H股，增持后，上实国际持有公司3.75亿股H股，占公司总股本的10.119%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0209","BK0183","BK0196","601607","BK0020","BK0184","BK0012","BK0188","BK0099","02607","BK0028","BK1197","BK0097","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680008622","title":"上海医药获得发明专利授权：“GITR结合蛋白及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2680008622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680008622?lang=zh_cn&edition=full","pubTime":"2026-11-02 03:59","pubTimestamp":1793563186,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示上海医药新获得一项发明专利授权，专利名为“GITR结合蛋白及其用途”，专利申请号为CN202210251210.2，授权日为2026年10月30日。专利摘要：本申请涉及一种GITR结合蛋白及其用途，具体涉及一种分离的抗原结合蛋白，包含HCDR3，所述HCDR3包含SEQ ID NO:3所示的氨基酸序列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK1197","BK0028","BK0012","BK0097","BK0183","BK0184","601607","BK0020","BK0187","BK0188","BK0209","02607","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679224240","title":"上海医药（601607）2026年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2679224240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679224240?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:22","pubTimestamp":1793416960,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期上海医药发布2026年三季报。根据财报显示，上海医药增收不增利。截至本报告期末，公司营业总收入2229.64亿元，同比上升3.67%，归母净利润45.86亿元，同比下降10.9%。持有上海医药最多的基金为工银创新动力股票，目前规模为11.8亿元，最新净值1.219，较上一交易日下跌0.08%，近一年下跌4.69%。2026年上半年，公司新增进口总代品规16个，实现销售收入超过200亿元，同比增长超15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100023945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0097","BK0183","601607","BK0184","BK0187","BK0196","BK0175","BK0209","BK0188","BK0099","02607","BK0020","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679423730","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于与上海复旦张江生物医药股份有限公司续签《销售及分销协议》暨日常关联交易的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2679423730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679423730?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:48","pubTimestamp":1793310512,"startTime":"0","endTime":"0","summary":"公司公告汇总上海医药集团股份有限公司关于与上海复旦张江生物医药股份有限公司续签《销售及分销协议》暨日常关联交易的公告2026年10月29日，上海医药与复旦张江续签《销售及分销协议》，有效期自2027年1月1日至2029年12月31日；2027年至2029年每年协议项下销售金额分别不超过8,600万元、9,000万元和9,600万元；交易按市场化定价原则进行，已获公司董事会审议通过，尚需复旦张江股东会批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000008978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688505","601607","BK0187","01349","BK0012","BK0239","BK0175","BK0028","BK0209","BK1191","BK0184","399441","BK1197","BK0188","BK0020","161726","BK0183","02607","BK0099","BK0196","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679179474","title":"上海医药：与上药集团签订房屋租赁框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2679179474","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679179474?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:51","pubTimestamp":1793267460,"startTime":"0","endTime":"0","summary":"南财智讯10月29日电，上海医药（02607.HK）公告，2026年10月29日，公司与上药集团签订房屋租赁框架协议，租赁期限自2027年1月1日起至2029年12月31日止。根据协议，上药集团将向公司提供房屋租赁服务。截至2027年、2028年及2029年12月31日止的三个年度，该协议项下交易的估计最高租金均不超过人民币1亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914392242.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914392242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK0020","BK0209","BK0175","BK0099","BK0097","601607","BK0188","BK0012","BK0028","BK0187","BK0184","BK0196","02607","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679847350","title":"上海医药：第三季度归母净利润10.82亿元 同比上升57.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679847350","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679847350?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:34","pubTimestamp":1793262893,"startTime":"0","endTime":"0","summary":"10月29日，上海医药(601607)公布2026年三季报，公司营业收入为2229.64亿元，同比上升3.7%；归母净利润为45.86亿元，同比下降10.9%；扣非归母净利润为33.74亿元，同比上升25.02%；经营现金流净额为53.47亿元，同比增长127.5%；EPS(全面摊薄)为1.24元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914187618.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914187618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678157451","title":"天士力、上海医药等纷纷终止管线研发：同质化竞争下，缺乏差异化跟随管线“及时止损”","url":"https://stock-news.laohu8.com/highlight/detail?id=2678157451","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678157451?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:35","pubTimestamp":1793000109,"startTime":"0","endTime":"0","summary":"数据显示，2025 年全球 HER2 阳性乳腺癌整体抗 HER2 药物市场中，ADC 类药物已占据 41.91% 的市场份额，TKI 仅占 15.02%，且差距仍在持续拉大。总体而言，I025-A的研发进度落后于整体赛道进展，而砍掉一个早期、无差异化优势的TKI项目对于上海医药来说或是一种及时止损。而在10月23日同日，天士力公告终止其化药1类PARP抑制剂TSL-1502胶囊的临床研究开发。除了上述两家公司，2026年以来，国内药企终止管线的案例明显增多。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792999673115111676","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0097","BK0188","600535","BK0183","BK0184","BK0175","BK0209","02607","BK0028","BK1197","601607","BK0099","BK0196","BK0239","BK0020","BK0187","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678137984","title":"上海医药：10月23日融资净买入1001.35万元，连续3日累计净买入1394.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678137984","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678137984?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:58","pubTimestamp":1792976280,"startTime":"0","endTime":"0","summary":"证券之星消息，10月23日，上海医药(601607)融资买入2199.48万元，融资偿还1198.13万元，融资净买入1001.35万元，融资余额7.27亿元，近3个交易日已连续净买入累计1394.24万元。融券方面，当 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261026/c681063666.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261026/c681063666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0175","BK0183","BK0099","BK0012","BK1197","BK0188","BK0020","BK0196","601607","BK0209","BK0187","BK0184","BK0097","02607","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136120","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136120?lang=zh_cn&edition=full","pubTime":"2026-10-26 02:50","pubTimestamp":1792954220,"startTime":"0","endTime":"0","summary":"公司公告汇总上海医药集团股份有限公司关于药品临床试验进展的公告上海医药决定终止I025-A研发项目的临床试验及后续开发。上海医药集团股份有限公司关于召开2026年第三季度业绩说明会的公告上海医药将于2026年11月2日10:00–11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司经营成果及财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0184","BK0196","BK0209","BK0175","02607","BK0187","BK1197","BK0020","BK0028","BK0097","BK0183","BK0099","601607","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677923879","title":"上海医药终止I025-A研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2677923879","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677923879?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:50","pubTimestamp":1792749000,"startTime":"0","endTime":"0","summary":"10月23日，上海医药（601607/02607）发布公告，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I025-A研发项目。I025-A是靶向HER2的酪氨酸激酶抑制剂（TKI），拟用于晚期实体瘤的治疗。2021年7月，该项目获国家药品监督管理局批准开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906392052.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906392052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0209","BK0187","BK0028","BK0184","BK0175","02607","601607","BK0183","BK0012","BK0020","BK0097","BK0196","BK1197","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677648543","title":"上海医药（601607）10月20日主力资金净卖出213.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677648543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677648543?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:35","pubTimestamp":1792542916,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月20日收盘，上海医药报收于16.45元，下跌1.56%，换手率0.37%，成交量10.22万手，成交额1.69亿元。10月20日的资金流向数据方面，主力资金净流出213.26万元，占总成交额1.27%，游资资金净流入1193.56万元，占总成交额7.08%，散户资金净流出980.3万元，占总成交额5.82%。融券方面，融券卖出4800.0股，融券偿还4100.0股，融券余量23.48万股，融券余额386.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","02607","BK0097","BK0099","BK0183","BK0209","BK0184","BK0020","BK0196","BK0012","601607","BK0187","BK0188","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872321","title":"【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674872321?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:26","pubTimestamp":1791804371,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于10月9日公布的信息整理，成都市前沿类脑人工智能创新中心有限公司天使轮融资，融资额2.5亿人民币，参与投资的机构包括上海医药，四川省中试平台有限公司，成都科创投集团。前沿类脑中心是一家脑机接口研发应用服务商，自主研发非侵入式脑机接口软硬件，包括双通道脑电+单通道心电多模态干电极采集模组，可实时捕捉脑电与生理信号。数据来源：天眼查APP以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200029706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["MUCmain","BK0183","BK0184","CNHmain","BK1197","BK0020","BK0028","UCmain","CYB","BK0209","02607","BK0012","MCNHmain","BK0196","BK0097","BK0175","601607","BK0188","BK0099","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674843048","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674843048","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674843048?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:43","pubTimestamp":1791740589,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月9日主力资金净流出1524.51万元，占总成交额5.3%； 公司公告汇总：氯维地平乳状注射液获国家药监局批准生产，公司已投入研发费用约5,220万元。公司公告汇总上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告上海医药集团股份有限公司下属上海上药第一生化药业有限公司收到国家药监局颁发的氯维地平乳状注射液《药品注册证书》，该药品符合药品注册有关要求，批准生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0097","BK0099","BK0012","BK0188","BK0187","BK0184","BK0028","BK1197","601607","BK0175","BK0196","BK0183","02607","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831293","title":"上海医药(601607.SH)：氯维地平乳状注射液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831293","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674831293?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:42","pubTimestamp":1791531746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药第一生化药业有限公司收到国家药品监督管理局颁发的关于氯维地平乳状注射液的《药品注册证书》，该药品获得批准生产。该药品主要用于治疗不适宜口服或预期口服药物治疗效果不佳的高血压。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","601607","BK0209","BK0020","BK0183","BK0175","BK0099","BK0188","BK0028","BK0097","02607","BK0012","BK0184","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794721597731,"stockEarnings":[{"period":"1week","weight":-0.0376},{"period":"1month","weight":-0.0387},{"period":"3month","weight":-0.0217},{"period":"6month","weight":-0.0095},{"period":"1year","weight":-0.0938},{"period":"ytd","weight":-0.0658}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是药品、医疗器械、大健康产品、医药商业。公司再度入选《财富》世界500强和《PharmExec》2026全球制药企业50强榜单，排名为第411位和第39位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}